Feeds:
Posts
Comments

Archive for the ‘Bone loss’ Category

URO TODAY: Prostate cancer tumors that have spread to the bones can be inhibited by targeting the bone and its micro-environment rather than the tumor alone. READ MORE>

Read Full Post »

NEW ENGLAND JOURNAL OF MEDICINE: A new drug just approved by the FDA for high risk prostate cancer patients suffering bone loss has performed well in a trial.

Denosumab was associated with increased bone mineral density at all sites and a reduction in the incidence of new vertebral fractures among men receiving androgen-deprivation therapy for non-metastatic prostate cancer.

Background: Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture.

We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-{kappa}B ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer.

Methods: In this double-blind, multicenter study, we randomly assigned patients to receive denosumab at a dose of 60 mg subcutaneously every 6 months or placebo (734 patients in each group).

The primary end point was percent change in bone mineral density at the lumbar spine at 24 months. Key secondary end points included percent change in bone mineral densities at the femoral neck and total hip at 24 months and at all three sites at 36 months, as well as incidence of new vertebral fractures.

Results: At 24 months, bone mineral density of the lumbar spine had increased by 5.6% in the denosumab group as compared with a loss of 1.0% in the placebo group (P<0.001); significant differences between the two groups were seen at as early as 1 month and sustained through 36 months.

Denosumab therapy was also associated with significant increases in bone mineral density at the total hip, femoral neck, and distal third of the radius at all time points.

Patients who received denosumab had a decreased incidence of new vertebral fractures at 36 months (1.5%, vs. 3.9% with placebo) (relative risk, 0.38; 95% confidence interval, 0.19 to 0.78; P=0.006). Rates of adverse events were similar between the two groups.

Researchers: Matthew R. Smith, M.D., Ph.D., Blair Egerdie, M.D., Narciso Hernández Toriz, M.D., Robert Feldman, M.D., Teuvo L.J. Tammela, M.D., Fred Saad, M.D., Jiri Heracek, M.D., Ph.D., Maciej Szwedowski, M.D., Chunlei Ke, Ph.D., Amy Kupic, M.A., Benjamin Z. Leder, M.D., Carsten Goessl, M.D., for the Denosumab HALT Prostate Cancer Study Group.

Read Full Post »

NEW YORK TIMES: Denosumab, a new drug to prevent fractures in men undergoing prostate cancer hormone treatment, is likely to get FDA approval for high risk cases only. READ MORE>

An FDA advisory committee has voted against three of four possible uses for breast and prostate cancer patients whose therapy can weaken bones. The FDA will decide in October.

Read Full Post »

NEW PROSTATE CANCER INFOLINK: New data published in the New England Journal of Medicine clearly suggests that bone-loss drug denosumab has a significant effect compared to placebo in men with prostate cancer. READ MORE>

Read Full Post »

CANCER FACTS.COM: A new drug injected twice a year reduced the risk of vertebral fractures by 62% compared to placebo in men with prostate cancer being treated with hormone blockade therapy, a new study shows. READ MORE>

Read Full Post »

E-CANCER MEDICAL SCIENCE: Oral bone loss drug sodium clodronate improves overall survival in men with advanced prostate cancer, but does not reduce the risk of death in men with localised disease, according to trial results published in The Lancet Oncology. READ MORE>

Read Full Post »

URO TODAY: Placement of zoledronic acid-releasing testicular prostheses has the potential to become the preferred clinical management tool for prostate cancer patients with bone metasthases after bilateral orchiectomy. READ MORE>

Read Full Post »

AUGUST 4: URO TODAY: Androgen deprivation therapy for prostate cancer has adverse side effects like reduced bone mass and increased risk for fracture, reduced lean mass and muscle strength, mood disturbance and increased fat mass.

An Australian investigation has examined the effects of long term exercise on reversing musculoskeletal-related side effects, and cardiovascular and diabetes risk factors in men receiving androgen deprivation. READ MORE>

Read Full Post »

JULY 17: NEW PROSTATE CANCER INFOLINK: Longer duration of continuous androgen deprivation therapy appears to increase risk of fragility fractures and diabetes, but not cardiac problems, according to a study of more than 19,000 prostate cancer patients in Ontario, Canada. READ MORE>

Read Full Post »

JULY 12: URO TODAY: Bone loss begins at 6 months with androgen deprivation therapy (ADT). A single infusion of zoledronic acid in patients receiving ADT reduces bone mineral loss and maintains bone mineral density (BMD) at least at 12 months during ADT. Further study is needed to determine the best dosing schedule to prevent ADT-induced bone loss in men with hormone-naive prostate carcinoma. READ MORE>

Read Full Post »

« Newer Posts - Older Posts »